Research Papers

25 of 107 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation i…
Mori Y; Takeuchi H; Tsutsumi Y.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Reasons for admission to a general medical hospital for patients taking clozapine.
Gee S; Almeida V; Hughes A; McMullen I; Taylor D.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Classic psychedelics, health behavior, and physical health.
Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study.
Pappa S; Kalniunas A; Sharma H; Raza-Syed A; Kamal M; Larkin F.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Increased left dorsolateral prefrontal cortex density following escitalopram intake during relearning: a randomized, pl…
Vanicek T; Reed MB; Seiger R; Godbersen GM; Klöbl M; Unterholzner J; Spurny-Dworak B; Gryglewski G; Handschuh P; Schmidt C; Kraus C; Stimpfl T; Rupprecht R; Kasper S; Lanzenberger R.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long…
Corbeil O; Essiambre AM; Béchard L; Roy AA; Huot-Lavoie M; Brodeur S; Chandrasena R; Thériault C; Crocker C; Melun JP; Tibbo P; Demers MF; Roy MA.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Pathophysiology, prognosis and treatment of tardive dyskinesia.
Takeuchi H; Mori Y; Tsutsumi Y.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Acceptability of cannabidiol in patients with psychosis.
Chesney E; Lamper D; Lloyd M; Oliver D; Hird E; McGuire P.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clin…
Paton C; Citrome L; Fernandez-Egea E; Rendora O; Barnes TRE.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric …
Lagreula J; de Timary P; Elens L; Dalleur O.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan.
Tien Y; Huang HP; Liao DL; Huang SC.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder:…
Chong TWH; Kootar S; Wilding H; Berriman S; Curran E; Cox KL; Bahar-Fuchs A; Peters R; Anstey KJ; Bryant C; Lautenschlager NT.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Vortioxetine as adjunctive therapy in the treatment of schizophrenia.
Redaelli S; Porffy L; Oloyede E; Dzahini O; Lewis G; Lobo M; Whiskey E; Shergill SS.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Millan MJ.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Clozapine blood level assessment using a point-of-care device: feasibility and reliability.
Kamhi-Nesher S; Taub S; Halimi S; Frenkel M; Azam M; Bormant G; Isakov H; Radzinsky D; Weizman A; Krivoy A.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Treatment strategies for clozapine-induced hypotension: a systematic review.
Tanzer TD; Brouard T; Pra SD; Warren N; Barras M; Kisely S; Brooks E; Siskind D.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review.
Singh R; Stogios N; Smith E; Lee J; Maksyutynsk K; Au E; Wright DC; De Palma G; Graff-Guerrero A; Gerretsen P; Müller DJ; Remington G; Hahn M; Agarwal SM.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Will psilocybin lose its magic in the clinical setting?
Hayes C; Wahba M; Watson S.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-act…
Lin CH; Chan HY; Wang FC; Hsu CC.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study.
Johannsen CF; Petersen TS; Nielsen J; Jørgensen A; Jimenez-Solem E; Fink-Jensen A.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and nove…
Kaufman Y; Carlini SV; Deligiannidis KM.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other ant…
Ma CH; Chan HY; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Chen WJ; Hwang TJ.
Ther Adv Psychopharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Cognitive effects of vortioxetine in older adults: a systematic review.
Bishop MM; Fixen DR; Linnebur SA; Pearson SM.
Ther Adv Psychopharmacol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Comparison of psychiatric symptoms between patients with major depression with higher and lower levels of high-sensitiv…
Okamoto N; Hoshikawa T; Ikenouchi A; Yoshimura R.
Ther Adv Psychopharmacol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Transcranial magnetic stimulation for post-traumatic stress disorder.
Petrosino NJ; Cosmo C; Berlow YA; Zandvakili A; van 't Wout-Frank M; Philip NS.
Ther Adv Psychopharmacol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared